Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Mice immunized with DNA encoding a modified Pseudomonas aeruginosa exotoxin A develop protective immunity against

J W Shiau1, T K Tang, Y L Shih

  • 1Department of Animal Physiology, Taiwan Livestock Research Institute, Hsinhau, Tainan, Taiwan.

Vaccine
|January 4, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Precise Measurement of the Chromoelectric Dipole Moment of the Charm Quark.

Physical review letters·2026
Same author

Precise Measurement of Matter-Antimatter Asymmetry with Entangled Hyperon-Antihyperon Pairs.

Physical review letters·2026
Same author

Observation of Λ[over ¯]p→K^{+}π^{+}π^{-}π^{0} and Λ[over ¯]p→K^{+}π^{+}π^{-}2π^{0}.

Physical review letters·2026
Same author

First Measurement of the D_{s}^{+}→K^{0}μ^{+}ν_{μ} Decay.

Physical review letters·2026
Same author

Observation of the Electromagnetic Radiative Decays of the Λ(1520) and Λ(1690) to γΣ^{0}.

Physical review letters·2026
Same author

Observation of a Threshold Enhancement in the π^{+}π^{-} Spectrum in ψ(3686)→π^{+}π^{-}J/ψ Decays.

Physical review letters·2026
Same journal

Adverse events and vaccine administration errors following RSV vaccination: Findings from the United States VAERS database, 2023-2025.

Vaccine·2026
Same journal

Protocol for a phase 3, randomized, double-blind clinical trial evaluating the safety and immunogenicity of the MVA-BN® vaccine against mpox in children aged 4 to less than 24 months in the Democratic Republic of the Congo: Data to guide future paediatric vaccination strategies.

Vaccine·2026
Same journal

Human systemic and mucosal immune responses support further exploration of a Klebsiella pneumoniae protein-based vaccine.

Vaccine·2026
Same journal

Corrigendum to "Immunogenicity and safety of a quadrivalent recombinant influenza vaccine manufactured in Iran (FluGuard) in volunteers aged 18-60 years: A double-blind, non-inferiority, randomized controlled trial" [Vaccine 42(9) (2024) 2254-2259].

Vaccine·2026
Same journal

Innovative webinar-based training to support evidence-to-recommendation decision-making by national immunization technical advisory groups: multi-country experience with hexavalent vaccines.

Vaccine·2026
Same journal

Under-vaccination as a systems failure: A Monte Carlo simulation of the 2025 CDC/ACIP hepatitis B birth-dose policy shift and multi-level intervention packages, 2025-2035.

Vaccine·2026
See all related articles

DNA vaccination using a modified Pseudomonas aeruginosa exotoxin A (PE) gene generated specific antibodies and provided protection against lethal PE toxin doses in mice. This demonstrates the potential of DNA vaccines for preventing exotoxin A intoxication.

Area of Science:

  • Molecular Biology
  • Immunology
  • Vaccinology

Background:

  • Pseudomonas aeruginosa exotoxin A (PE) is a potent bacterial toxin responsible for severe infections.
  • Developing effective vaccines against PE is crucial for preventing P. aeruginosa-associated diseases.
  • DNA vaccination offers a promising strategy for inducing immune responses against various antigens.

Purpose of the Study:

  • To assess the efficacy of a DNA vaccine encoding a modified Pseudomonas aeruginosa exotoxin A (PE) gene.
  • To evaluate the in vivo expression, immunogenicity, and protective potential of the recombinant DNA construct.

Main Methods:

  • Construction of a recombinant plasmid containing the C-terminally deleted PE gene in an expression vector.
  • Transient transfection and Western blot assay to confirm expression in 3T3 cells.

Related Experiment Videos

  • Intramuscular DNA injection into BALB/c mice, followed by assessment of antibody production and toxin challenge.

    • Main Results:

    • Successful expression of the recombinant PE protein in vitro was confirmed.
    • Mice vaccinated with the PE DNA vaccine developed specific anti-PE antibodies.
    • Vaccinated mice exhibited significant protection against lethal doses of P. aeruginosa exotoxin A.

    Conclusions:

    • DNA vaccination with the engineered PE gene induces a protective immune response in vivo.
    • The developed DNA vaccine strategy shows potential for safeguarding against P. aeruginosa exotoxin A intoxication.
    • Further research into this DNA vaccine approach could lead to novel therapeutic strategies.